Bharat biotech's COVID-19 vaccine Covaxin gets DCGI nod for phase 3 clinical trial
The Drugs Controller General of India (DCGI) on Friday permitted Bharat Biotech to conduct phase 3 clinical trials of its indigenously developed COVID-19 vaccine with certain conditions, officials said.
A subject expert committee on COVID-19 at the Central Drugs Standard Control Organisation (CDSCO) had recommended granting permission to the Hyderabad-based firm for conducting phase 3 clinical trial of its vaccine 'Covaxin' after assessing the safety and immunogenicity data of the phase 1 and 2 trials.
Comments
Post a Comment